Guide to the Care and Use of Experimental Animals

Total Page:16

File Type:pdf, Size:1020Kb

Guide to the Care and Use of Experimental Animals GUIDE TO THE CARE AND USE OF EXPERIMENTAL ANIMALS Volume 1 1993 Edited by: Ernest D. Olfert, DVM; Brenda M. Cross, DVM; and A. Ann McWilliam Editors: Mrs A.A. McWilliam Dr E.D. Olfert Dr B.M. Cross Information Officer Director Asssistant Director Canadian Council on Animal Animal Resources Centre Animal Resources Centre Care University of Saskatchewan University of Saskatchewan 1000-151 Slater Street Saskatoon, Saskatchewan S7N 0W0 Saskatoon, Saskatchewan S7N 0W0 Ottawa, Ontario K1P 5H3 ©Canadian Council on Animal Care, 1993 ISBN: 0-919087-18-3 Citing certain devices or manufacturers is not to be perceived as the endorsement of the Canadian Council on Animal Care (CCAC) of one particular product over another. In keeping with the CCAC policy of revising statements and guidelines as needed, users of this Guide are encouraged to forward any comments to the Secretariat. Table of Contents DEDICATION PREFACE FOREWORD ACKNOWLEDGEMENTS CONTRIBUTORS I. RESPONSIBILITY FOR THE CARE AND USE OF EXPERIMENTAL ANIMALS A. NATIONAL LEVEL 1. Evolution of the Canadian Council on Animal Care 2. The Contemporary Council 3. CCAC's Assessment Program 4. CCAC Position Statements 5. Legislation Governing Experimental Animals 6. Pre-University Use of Animals B. LOCAL LEVEL 1. The Institutional Animal Care Committee 2. Terms of Reference for Animal Care Committees 3. The Veterinarian 4. Animal Care Personnel C. REFERENCES II. LABORATORY ANIMAL FACILITIES A. INTRODUCTION B. LOCATION C. MECHANICAL SERVICES D. DESIGN E. MAJOR FUNCTIONAL DIVISIONS 1. Animal Reception Area 2. Conditioning Rooms 3. Holding Rooms 4. Quarantine/Isolation Rooms 5. Experimental and Treatment Facilities 6. Support Facilities 7. Personnel, Office and Reception Areas 8. Facilities for Personnel F. SECURITY G. CONSTRUCTION GUIDELINES FOR ANIMAL ROOMS 1. Floors and Drains 2. Walls and Ceilings 3. Doors 4. Windows 5. Corridors 6. Services H. CAGING 1. Shoebox Cages 2. Larger Solid Bottom Caging 3. Suspended Cages 4. Other Cages I. REFERENCES III. THE ENVIRONMENT A. CLIMATE CONTROL 1. Temperature 2. Humidity 3. Ventilation 4. Lighting B. OTHER ENVIRONMENTAL FACTORS 1. Noise 2. Chemicals 3. Bedding 4. Population Density and Space Limitations C. MICROBIOLOGICAL CONTROL 1. Conventional Facilities 2. Barrier Facilities 3. Biohazard Containment D. CHEMICAL AND RADIOISOTOPE UNITS E. REFERENCES IV. FARM ANIMAL FACILITIES AND ENVIRONMENT A. FACILITIES B. SPECIFIC ENVIRONMENTAL CONSIDERATIONS 1. Cattle 2. Sheep 3. Swine 4. Horses 5. Poultry C. PEST CONTROL D. REFERENCES V. LABORATORY ANIMAL CARE A. INTRODUCTION B. GENERAL PRACTICES 1. Reception 2. Conditioning/Quarantine 3. Holding (Maintenance) 4. Identification and Records C. CARE OF THE ANIMAL 1. Food 2. Water 3. Exercise D. CARE OF THE FACILITY 1. Cleaning and Sanitation 2. Waste Disposal 3. Vermin Control 4. Holiday and Emergency Care E. REFERENCES VI. SOCIAL AND BEHAVIORAL REQUIREMENTS OF EXPERIMENTAL ANIMALS A. INTRODUCTION 1. What is Animal Well-being or Welfare? 2. Environmental Enrichment 3. Group Formation 4. Position Statement B. ANIMALS USED IN AGRICULTURAL RESEARCH 1. Introduction 2. Animal Stress 3. Housing and Husbandry 4. General Principles C. ANIMALS (LARGE) HELD IN METABOLISM CAGES 1. Conditioning 2. Size of Metabolism Crates 3. Contact with Other Animals 4. Pre-, During and Post-Experiment Checks 5. Observing Changes in Behavior 6. Duration of Confinement 7. Exceptional Circumstances D. CATS 1. Introduction 2. Behavioral Enrichment 3. Social Peers 4. Enrichment Devices (Artificial Appliances) 5. Food Gathering Activities 6. Control of the Environment 7. Housing 8. Maternal Behavior 9. Random-Source vs. Purposebred Animals E. DOGS 1. Introduction 2. Breed Differences 3. Criteria for Assessing Well-being 4. Housing 5. Socialization to People 6. Enrichment Devices (Artificial Appliances) 7. Exercise F. NON-HUMAN PRIMATES 1. Introduction 2. Interpretation of the Behavioral and Morphological Postures 3. Distinctive Characteristics 4. Assessing Social and Behavioral Well-being 5. Ways of Promoting Social and Behavioral Well-being 6. Disposition 7. Summary G. RODENTS AND RABBITS 1. Introduction 2. Behavioral Enrichment and Social Peers 3. Enrichment Devices (Artificial Appliances) 4. Caging and Bedding 5. Food Gathering 6. Control of the Environment H. WILDLIFE HELD IN THE LABORATORY I. REFERENCES VII. SPECIAL PRACTICES A. ANIMAL ACQUISITION 1. Procurement 2. Transportation 3. Breeding 4. Breeding Transgenic Animals 5. Animal Models with Special Needs 6. Identification of the Sexes B. RESTRAINT AND MANIPULATIONS 1. Physical Restraint 2. Implantation, Cannulation and Sampling 3. Bleeding 4. Motivation Procedures C. REFERENCES VIII. OCCUPATIONAL HEALTH AND SAFETY A. REGULATORY REQUIREMENTS B. BILOGICAL HAZARDS C. ZOONOSES D. PROCEDURES FOR WORKING WIHT NON-HUMAN PRIMATES E. ALLERGIES F. PHYSICAL INJURIES AND CHEMICAL HAZARDS G. RADIATION AND ULTRAVIOLET LIGHT H. REFERENCES IX. STANDARDS FOR EXPERIMENTAL ANIMAL SURGERY A. INTRODUCTION B. FACILITIES FOR SURVIVAL SURGERY C. PRE-OPERATIVE PLANNING AND ANIMAL PREPARATION D. SURGICAL PROCEDURES AND INTRA-OPERATIVE NURSING CARE E. POST-OPERATIVE RECOVERY AND SUPPORT F. REFERENCES X. CONTROL OF ANIMAL PAIN IN RESEARCH, TEACHING AND TESTING A. INTRODUCTION B. WHAT IS ANIMAL PAIN? C. GUIDELINES D. THE ROLE OF THE VETERINARIAN IN REDUCING PAIN E. SIGNS OF PAIN AND DISTRESS F. ANALGESIC AGENTS 1. Opioid Agonists 2. Opioid Agonist/Antagonists 3. Opioid Antagonists 4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 5. Analgesia provided by Local Anesthetics 6. Neuroleptanalgesics G. AREAS FOR FUTURE STUDY H. REFERENCES XI. ANESTHESIA A. MANAGEMENT OF ANESTHESIA 1. General 2. Handling the Patient 3. Fasting 4. Anticholinergics B. TRANQUILLIZERS AND SEDATIVES C. GENERAL ANESTHETICS 1. Dissociative Anesthetics 2. Barbiturates 3. Chloralose 4. Urethane (Urethan, Ethyl Carbamate) 5. SaffanTM 6. Tribomoethanol (Avertin) 7. Non-specific Injectable Anesthetic Antagonists 8. Inhalant Anesthetics D. MUSCLE RELAXANTS 1. Glyceryl Guiacolate 2. Neuromuscular Blocking Agents E. LOCAL AND REGIONAL ANESTHETICS F. ANIMAL HYPNOSIS (TONIC IMMOBILITY) G. SPECIES CONSIDERATIONS H. REFERENCES XII. EUTHANASIA A. INTRODUCTION B. CRITERIA FOR A HUMANE DEATH C. PAIN AND STRESS D. MECHANISMS FOR CAUSING DEATH E. METHODS USED FOR EUTHANASIA 1. Physical 2. Non-inhalant Pharmacologic Agents 3. Inhalant Anesthetics 4. Non-anesthetic Gases F. SPECIFIC SPECIES 1. Amphibians, Fishes and Reptiles 2. Domestic Animals Killed for Food 3. Fur-bearing Animals G. TISSUE EFFECTS OF EUTHANASIA METHODS 1. Direct Effects 2. Indirect Effects H. EFFECT ON OBSERVERS I. EUTHANASIA STATEMENTS--OTHER AGENCIES J. REFERENCES XIII. THE USE OF ANIMALS IN PSYCHOLOGY A. THE SCIENTIST B. RESEARCH C. INSTRUCTION D. REFERENCES XIV. GUIDELINES FOR THE USE OF ANIMALS IN NEUROSCIENCE RESEARCH A. INTRODUCTION B. FACTORS THAT RELATE TO THE DESIGN OF EXPERIMENTS C. FACTORS THAT RELATE TO THE CONDUCT OF EXPERIMENTS APPENDICES I. Housing and Environment II. Breeding and Reproduction Data III. Physiological and Nutritional Parameters IV. Hematology V. Clinical Biochemistry Reference Values VI. Serum Electrolyte Reference Values VII. Zoonoses--Experimental Animals to Man A. Bacterial Diseases B. Rickettsial Diseases C. Arbovirus Diseases D. Other Virus Diseases E. Fungal and Protozoan Diseases VIII. Common Bleeding Sites IX. Tranquillizer, Sedative and Anticholinergic Drug Dosages X. Analgesic Drug Dosages XI. Injectable Anesthetic Agents--Dosage XII. Anesthetic and Sedative Drug Dosage--Amphibians and Reptiles XIII. Anesthetic and Sedative Drug Dosage--Fishes XIV. Methods for Euthanasia by Species XV. CCAC Position Statements A. Ethics of Animal Investigation B. Categories of Invasiveness in Animal Experiments C. CCAC Guidelines on Acceptable Immunological Procedures XVI. Journals Held by CCAC XVII. Glossary DEDICATION The Canadian Council on Animal Care dedicates this 2nd Edition of Volume 1 of its Guide to the Care and Use of Experimental Animals to CCAC's founder and executive director until his retirement in 1992, Dr. Harry Rowsell. His vision and devotion to the cause of experimental animal welfare have set an example which many seek to emulate, but few achieve. PREFACE In 1961, the Committee on Animal Care of the Canadian Federation of Biological Societies (CFBS) prepared a one-page placard outlining "Guiding Principles for the Care of Experimental Animals". These principles were quickly approved by most national scientific associations and, despite their brevity, addressed essentially the same basic principles of animal care embodied in this 2nd Edition of Volume 1 of the Canadian Council on Animal Care (CCAC) Guide to the Care and Use of Experimental Animals. The hundreds of pages of information contained in the current two volumes of the Guide represent steps in the evolution of efforts by the CCAC to provide the means by which the use of animals in research, teaching and testing in Canada can be performed in accord with basic principles of humane treatment. The CCAC is deeply indebted to the many veterinarians, animal care employees, humane society members, administrators, scientists, and others who have willingly contributed time and expertise to its programs and projects. This edition of Volume 1 of the Guide is only one example of the many CCAC- directed activities that owe their existence and success to the tremendous generosity and good will of these Canadians. Their broad participation in animal welfare is one of the most important, and least-
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical
    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Abstract/Summary Development Targets in Anaesthetic
    University of Plymouth PEARL https://pearl.plymouth.ac.uk Faculty of Health: Medicine, Dentistry and Human Sciences Peninsula Medical School 2017-12-01 Thiopental to desflurane - an anaesthetic journey. Where are we going next? Sneyd, J http://hdl.handle.net/10026.1/9849 10.1093/bja/aex328 British Journal of Anaesthesia Oxford University Press (OUP) All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author. Thiopental to desflurane - an anaesthetic journey. Where are we going next? Abstract/summary Development targets in anaesthetic pharmacology have evolved from minimising harm caused by unwanted effects through an era in which rapid onset and offset of drug effect were prioritised. Today’s anaesthetists have access to a library of effective drugs whose characteristics offer controllable hypnosis, analgesia and paralysis with manageable off-target effects. The availability of these agents at generic prices inhibits commercial interest and this is reflected in the limited number of current anaesthetic drug development projects. Recently, questions around neonatal neurotoxicity, delirium and post-operative cognitive dysfunction have stimulated research to characterise these phenomena and explain them in mechanistic terms. Emergent basic science from these enquiries together with exploration of possible effects of anaesthetic drug choice on patient outcomes from cancer surgery may yield new targets for drug discovery. The past 40 years have seen extraordinary developments in anaesthetic pharmacology culminating in a limited but versatile set of hypnotics, analgesics and muscle relaxants adaptable to every clinical situation.
    [Show full text]
  • A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl
    International Society for Anaesthetic Pharmacology Preclinical Pharmacology Section Editor: Markus W. Hollmann Anesthetic Clinical Pharmacology Section Editor: Ken B. Johnson Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether-β-Cyclodextrin Colin S. Goodchild, MA, MB, BChir, PhD, FRCA, FANZCA, FFPMANZCA, Juliet M. Serrao, MB, BS, PhD, FRCA, Anton Kolosov, MSc, PhD, and Ben J. Boyd, PhD * 07/29/2020 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3bhnalqTQiPv0Qe2oObD6Borpr8ynxk/m7SI60vZRsDj7xUAQhxAE7Q== by https://journals.lww.com/anesthesia-analgesia from Downloaded † * ‡ BACKGROUND: Alphaxalone is a neuroactive steroid anesthetic that is poorly water soluble. Downloaded It was formulated in 1972 as Althesin® using Cremophor® EL, a nonionic surfactant additive. The product was a versatile short-acting IV anesthetic used in clinical practice in many coun- from tries from 1972 to 1984. It was withdrawn from clinical practice because of hypersensitivity https://journals.lww.com/anesthesia-analgesia to Cremophor EL. In the investigations reported here, we compared the properties of 3 anes- thetics: a new aqueous solution of alphaxalone dissolved in 7-sulfobutyl-ether-β-cyclodextrin (SBECD, a water-soluble molecule with a lipophilic cavity that enables drug solubilization in water); a Cremophor EL preparation of alphaxalone; and propofol. METHODS: Two solutions of alphaxalone (10 mg/mL) were prepared: one using 13% w/v solu- tion of SBECD in 0.9% saline (PHAX) and the other a solution of alphaxalone prepared as described in the literature using 20% Cremophor EL (ALTH). A solution of propofol (10 mg/mL; PROP) in 10% v/v soya bean oil emulsion was used as a comparator anesthetic. Jugular IV cath- by eters were implanted in male Wistar rats (180–220 g) under halothane anesthesia.
    [Show full text]
  • Mar. Biol. Ass. India, 1965, 8 (1): 28-56 EFFECTS OF
    /. Mar. biol. Ass. India, 1965, 8 (1): 28-56 EFFECTS OF ANAESTHETICS ON THE BEHAVIOUR OF MULLET FINGERLINGS AND THE SCOPE OF USING THESE IN DIFFERENT FISHERY PROCEDURES-!* By V. S. DURVE** AND S. K. DHARMA RAJA Central Marine Fisheries Research Institute, Mandapam Camp INTRODUCTION THE use of anaesthetics in fishery work, mainly in the transport of live-fish and also in handling fish for tagging, fin-clipping, weighing and stripping has been recognised by fishery workers everywhere. In live-fish transport, anaesthetics are useful in lowering the metabolic activity of fish, which facilitates the transport of more fish in a given quantity of water for a longer time. It has also been proved that anaes­ thetics make the otherwise time consuming work of tagging and fin-clipping much easier and also lower the mortality of the fish due to handling. Considerable effort has gone into a search for a proper anaesthetic and its different concentrations to give varying degrees of anaesthesia useful for works from tagging to transport of live-fish. Several methods have been used to produce anaesthesia. Abramowitz (1937), Parker (1937, 1939), Abramowitz et al. (1940) Osborn (1938, 1941) immersed fishes in crushed ice or ice water. Haskell (1940) employed electric shock to produce a paralysis lasting about two minutes. It is doubtful whether the anaesthesia induced by these methods is similar to that induced by chemicals. The disadvantages of such methods have been discussed by Pickford and Atz (1957). Chemicals used to anaesthetize fishes include Ether, Urethane, Chlorobutanol, MS-222 SANDOZ, Sodium Amytal and Chloral Hydrate, besides 8 to 9 others.
    [Show full text]
  • HISTAMINE RELEASE AFTER INTRAVENOUS APPLICATION of SHORT-ACTING HYPNOTICS a Comparison of Etomidate, Althesin (CT1341) and Propanidid*
    Brit. J. Anaesth. (1973), 45, 1097 HISTAMINE RELEASE AFTER INTRAVENOUS APPLICATION OF SHORT-ACTING HYPNOTICS A Comparison of Etomidate, Althesin (CT1341) and Propanidid* A. DOENICKE, W. LORENZ, R. BEIGL, H. BEZECHY, G. UHLIG, L. KALMAR, B. PRAETORIUS AND G. MANN SUMMARY The subject of histamine release was investigated in 16 volunteers by means of plasma histamine determination after the administration of etomidate, Althesin, propanidid, and Cremophor EL. Althesin and propanidid caused release of histamine in various degrees of frequency. Blood pressure changes were rather pronounced with both anaesthetic agents; tachycardia reached its mavimiim in the first and second minute, which seems to be an argument against histaminp release as the underlying cause of this reaction. Histamine was, indeed, only released to such an extent (with the exception of one borderline case) that no clinical symptoms other than secretion of gastric juice and erythema were to be expected. After the application of etomidate and Cremophor EL an increase in plasma histamine was not detectable. Changes in the differential Wood picture in terms of a decrease in basophils only occurred after Althesin and propanidid; not, however, after etomidate and Cremophor EL. Etomidate is, therefore, the first hypnotic drug for intravenous application which is unlikely to cause chemical histaminp release. 1 The increasing incidence of anaphylactic and anaphy- release into the circulatory system (max. about 5 lactoid reactions after the administration of anaes- minutes after the injection) (Lorenz et al., 1972b). thetic agents, muscle relaxants and plasma substi- Two new short-acting anaesthetics (hypnotics) are tutes in recent years has enhanced the clinicians' under clinical investigation at present, i.e.
    [Show full text]
  • {Download PDF}
    NO! PDF, EPUB, EBOOK Marta Altes | 32 pages | 15 May 2012 | Child's Play International Ltd | 9781846434174 | English | Swindon, United Kingdom trình giả lập trên PC và Mac miễn phí – Tải NoxPlayer Don't have an account? Sign up here. Already have an account? Log in here. By creating an account, you agree to the Privacy Policy and the Terms and Policies , and to receive email from Rotten Tomatoes and Fandango. Please enter your email address and we will email you a new password. We want to hear what you have to say but need to verify your account. Just leave us a message here and we will work on getting you verified. No uses its history-driven storyline to offer a bit of smart, darkly funny perspective on modern democracy and human nature. Rate this movie. Oof, that was Rotten. Meh, it passed the time. So Fresh: Absolute Must See! You're almost there! Just confirm how you got your ticket. Cinemark Coming Soon. Regal Coming Soon. By opting to have your ticket verified for this movie, you are allowing us to check the email address associated with your Rotten Tomatoes account against an email address associated with a Fandango ticket purchase for the same movie. Geoffrey Macnab. Gripping and suspenseful even though the ending is already known. Rene Rodriguez. The best movie ever made about Chilean plebiscites, No thoroughly deserves its Oscar nomination for Best Foreign Film. Anthony Lane. Soren Andersen. Calvin Wilson. A cunning and richly enjoyable combination of high-stakes drama and media satire from Chilean director Pablo Larrain.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]